UTI Asset Management Company LtdQ4 FY23

UTI Asset Management Company Ltd Q4 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹878P/E: 21.7Market Cap: ₹11.6K CrSector: Capital Markets

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3
  • Focus on improving fund performance to drive inflows and market share, especially in equity funds.
  • Strategic launch of a BAF product pending SEBI approval to boost fundraising.
  • Continuous engagement with distributors, including banking channels, to promote products.
  • Expansion plans include opening 29 new branches targeting Tier 3 and Tier 4 cities with a break-even expected in 1.5-2 years.
  • Digital strategy enhancement with hiring of data analysts and improving digital platforms to engage young investors.
  • Staff cost expected to grow moderately (~3.5%) due to controlled salary increases and retirements.
  • Payout ratio increased from 48% to 63% in FY22, expected to be maintained or improved, subject to board decisions.
  • Expectation to stabilize or improve yields with a focus on new AUM and managing competitive dynamics.
  • Overall aim to regain and grow market share through performance, distribution expansion, and digital initiatives.

See what UTI Asset Management Company Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

- UTI Capital Pvt. Ltd. is building its business and managing several active debt funds with current fundraisings: - UTI Structured Debt Opportunities Fund (SDOF) III launched in September 2022, currently in fundraising and investing stage with AUM Rs. 300 crore. - For UTI International, there are plans for new fund launches in the U.S. market; legal and registration expenses are expected but precise costs are not finalized. - No direct equity New Fund Offers (NFOs) launched in FY23, but several ETFs and fund of funds were introduced. - Approval for launching a Balanced Advantage Fund (BAF) is awaited from SEBI, which is strategized to aid future fundraising. - The company is focusing on expanding geographical reach and digital presence to support product sales and fund inflows. Thus, active new fundraising is ongoing primarily through debt-focused products at UTI Capital and planned product launches internationally and in hybrid categories post regulatory approval.

See what UTI Asset Management Company Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Opening 29 new branch offices across India in FY 2023-24, with an estimated investment of around Rs. 3.2 crore; branches expected to break even in 1.5 to 2 years. (Page 16-17)
  • Investments in digital strategy: expanding a 14-member digital team, hiring data analysts, and upgrading digital and IT assets to enhance investor engagement via apps and websites. (Page 18)
  • Significant investments in building capabilities and infrastructure for investment teams, including customized training and development programs. (Page 4)
  • UTI Capital is building alternative investment products with plans to launch funds such as Real Estate Opportunities Fund; has made net loss of Rs. 3.3 crore due to investments to build this business. (Page 5, 9)
  • UTI International expanding operations with new subsidiary UTI Investments America for North American market; incurring legal and registration expenses for new fund launches. (Page 21, 9)
  • Past significant investments in IT infrastructure and security, with reduced IT investments expected going forward. (Page 23)

Track UTI Asset Management Company Ltd — get its next earnings analysis in your feed

How does UTI Asset Management Company Ltd rank vs peers in Capital Markets?

Pro feature
ThisUTI Asset Management Company Ltd
Rev 3Mar 3

How does UTI Asset Management Company Ltd rank in Capital Markets?

Compare UTI Asset Management Company Ltd against every Capital Markets company (Q4 FY23) on revenue, margins and earnings-call signals.

View Capital Markets leaderboard →

Others in Capital Markets this season

  • CARE Ratings Ltd (Q1 FY25)

    78.92 Crs, up 19% YoY (Page 13) . Key concall takeaways from CARE Ratings Ltd's Q1 FY25 earnings call — and how it ranks against sector peers.

  • ICRA Ltd (Q3 FY25)

    Q3 FY2025 Revenue: ₹120.9 crore, up 5.5% YoY from ₹114.6 crore in Q3 FY2024 (Page 6). Key concall takeaways from ICRA Ltd's Q3 FY25 earnings call — and how it…

  • CARE Ratings Ltd (Q3 FY26)

    90.24 Crs, up 15% YoY (Page 12, 2) . Key concall takeaways from CARE Ratings Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.

  • CARE Ratings Ltd (Q1 FY27)

    111.68 Cr, up 18.9% YoY (Page 2, 13) . Key concall takeaways from CARE Ratings Ltd's Q1 FY27 earnings call — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →